Dr Reddy's unveils generic version of Lyrica capsules in US for treating neuropathic pain

Published On 2019-07-31 03:46 GMT   |   Update On 2019-07-31 03:46 GMT

Dr Reddy's Labs' Pregabalin capsule is a generic version of C P Pharmaceuticals International C V's Lyrica capsules which had US sales of around $5,462 million for the twelve months ended May 2019.


New Delhi: Dr Reddy's Laboratories on July 30 said it has launched Pregabalin capsules, used to treat neuropathic pain, in the US market.


The company has launched the product after getting approval from the US Food and Drug Administration (USFDA), Dr Reddy's Labs said in a statement.


Read Also: Patent Infringement: AstraZeneca moves US court against Dr Reddy’s on a generic version of blockbuster Brilinta


The product is a generic version of C P Pharmaceuticals International C V's Lyrica capsules which had US sales of around $5,462 million for the twelve months ended May 2019.




The Hyderabad-based firm said its Pregabalin capsules are available in strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg in bottle count sizes of 90.





Based in Hyderabad, Dr Reddys was founded by Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited, of Hyderabad, India.




Read Also: Dr Reddys unveils generic version of Rozerem Tablets in US for treating insomnia
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News